| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1001381566 |
| P356 | DOI | 10.2165/00003495-199754050-00002 |
| P698 | PubMed publication ID | 9360056 |
| P2093 | author name string | Perfect JR | |
| Alexander BD | |||
| P2860 | cites work | Selection of Candida glabrata in pediatric bone marrow transplant recipients receiving fluconazole | Q72520371 |
| Candida glabrata, Candida krusei, non-albicans Candida spp., and other fungal organisms in a sixty-bed national cancer center in 1989-1993: no association with the use of fluconazole | Q72588936 | ||
| Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer | Q72675254 | ||
| Resistance to amphotericin B associated with defective sterol delta 8-->7 isomerase in a Cryptococcus neoformans strain from an AIDS patient | Q72800846 | ||
| Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor | Q72909151 | ||
| Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient | Q74145459 | ||
| Molecular cloning and characterization of a novel gene of Candida albicans, CDR1, conferring multiple resistance to drugs and antifungals | Q28293585 | ||
| Positive interaction of nikkomycins and azoles against Candida albicans in vitro and in vivo | Q28316948 | ||
| Topical pharmacology of imidazole antifungals | Q28333823 | ||
| In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus | Q28369094 | ||
| In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans | Q28379195 | ||
| Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance | Q28379619 | ||
| Beta-Lactam antibiotics (1). | Q30462185 | ||
| Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy | Q33357288 | ||
| Phase I trial of recombinant human macrophage colony-stimulating factor in patients with invasive fungal infections | Q33380627 | ||
| Analysis of a Candida albicans gene that encodes a novel mechanism for resistance to benomyl and methotrexate | Q33630438 | ||
| Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B. | Q33751411 | ||
| Candida albicans gene encoding resistance to benomyl and methotrexate is a multidrug resistance gene | Q33752151 | ||
| Azole resistance in oropharyngeal Candida albicans strains isolated from patients infected with human immunodeficiency virus | Q33762325 | ||
| Amphotericin B: 30 years of clinical experience | Q34028160 | ||
| Infection due to Penicillium marneffei, an emerging pathogen: review of 155 reported cases | Q34398225 | ||
| Antifungal agents: chemotherapeutic targets and immunologic strategies | Q34400044 | ||
| Resistance of Candida species to fluconazole | Q35110522 | ||
| Development of resistance to 5-fluorocytosine in Candida parapsilosis during therapy. | Q54077208 | ||
| Correlation of in-vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patients. | Q54172080 | ||
| Antifungal prophylaxis with low-dose fluconazole during bone marrow transplantation. The Bone Marrow Transplantation Team. | Q54190673 | ||
| Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. | Q54194571 | ||
| Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. | Q54215184 | ||
| HIV and multidrug resistance | Q54233451 | ||
| Foscarnet treatment of cytomegalovirus gastrointestinal infections in acquired immunodeficiency syndrome patients who have failed ganciclovir induction. | Q54244016 | ||
| Purification of the 170- to 180-kilodalton membrane glycoprotein associated with multidrug resistance. 170- to 180-kilodalton membrane glycoprotein is an ATPase. | Q54390050 | ||
| The lipid composition of azole-sensitive and azole-resistant strains of Candida albicans. | Q54423176 | ||
| Azole resistance in Candida albicans. | Q54484937 | ||
| Long-term therapy of chronic mucocutaneous candidiasis with ketoconazole: experience with twenty-one patients. | Q54503124 | ||
| Mode of Action of 5-Fluorocytosine and Mechanisms of Resistance | Q54631149 | ||
| In vivo interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae | Q57908432 | ||
| Pradimicin, a novel class of potent antifungal antibiotics | Q67980659 | ||
| Amphotericin B-resistant yeast infection in severely immunocompromised patients | Q68136440 | ||
| 5-Fluorocytosine resistance in Candida spp. and Torulopsis glabrata | Q69260125 | ||
| Fatal disseminated candidiasis due to amphotericin-B-resistant Candida guilliermondii | Q70047840 | ||
| Correlation of in Vitro Susceptibility Test Results with in Vivo Response: Flucytosine Therapy in a Systemic Candidiasis Model | Q70257684 | ||
| In-vitro resistance to imidazole antifungals in Candida albicans | Q70375025 | ||
| Antifungal prophylaxis: to prevent or not | Q70606608 | ||
| Fluconazole-resistant Candida albicans after long-term suppressive therapy | Q70677847 | ||
| The Development Of Resistance By Candida Species To Polyene Antibiotics In Vitro | Q71153462 | ||
| Serum therapy for Cryptococcal meningitis | Q71373532 | ||
| Cytomegalovirus encephalitis resistant to anti-cytomegalovirus therapy | Q71971314 | ||
| Infection due to fluconazole-resistant Candida in patients with AIDS: prevalence and microbiology | Q71972430 | ||
| Correlation between in vitro susceptibility of Candida albicans and fluconazole-resistant oropharyngeal candidiasis in HIV-infected patients | Q72430003 | ||
| Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi | Q35111403 | ||
| Cross-resistance to polyene and azole drugs in Cryptococcus neoformans | Q35116225 | ||
| Use of amphotericin B with azole antifungal drugs: what are we doing? | Q35117932 | ||
| Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters | Q35120105 | ||
| Correlation between rhodamine 123 accumulation and azole sensitivity in Candida species: possible role for drug efflux in drug resistance. | Q35122459 | ||
| Fungal virulence genes as targets for antifungal chemotherapy. | Q35125420 | ||
| Susceptibilities of Candida albicans multidrug transporter mutants to various antifungal agents and other metabolic inhibitors | Q35127954 | ||
| Reduced accumulation of drug in Candida krusei accounts for itraconazole resistance | Q35128677 | ||
| Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia | Q35131728 | ||
| Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus | Q35137093 | ||
| In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds | Q35137879 | ||
| 5-fluorocytosine resistance in Cryptococcus neoformans | Q35650214 | ||
| Susceptibility to 5-fluorocytosine and prevalence of serotype in 402 Candida albicans isolates from the United States | Q35716914 | ||
| Candida albicans resistance to 5-fluorocytosine: frequency of partially resistant strains among clinical isolates | Q35761208 | ||
| Modulation of host defenses by cytokines: evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts | Q35811363 | ||
| Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients | Q35819117 | ||
| Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1. | Q35900199 | ||
| Susceptibility testing of fungi: current status of the standardization process | Q35903839 | ||
| Treatment of acyclovir-resistant herpes simplex virus infections in patients with AIDS | Q36197267 | ||
| Development of Resistance to Amphotericin B in Candida lusitaniae Infecting a Human | Q36482211 | ||
| Susceptibility testing of fungi: current status of correlation of in vitro data with clinical outcome | Q36528018 | ||
| Genetic and Physiological Aspects of Resistance to 5-Fluoropyrimidines in Saccharomyces cerevisiae | Q36778878 | ||
| Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Te | Q36855581 | ||
| Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection. | Q37091074 | ||
| Candida albicans genotyping in studies with patients with AIDS developing resistance to fluconazole. | Q37141720 | ||
| Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: persistence of Candida albicans strains with the same genotype. | Q37166301 | ||
| Trichosporon beigelii, an emerging pathogen resistant to amphotericin B | Q37186512 | ||
| Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis | Q37195950 | ||
| Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests | Q37251197 | ||
| Fungal infections and the search for novel antifungal agents. Opening remarks | Q39554263 | ||
| Flucytosine | Q39618637 | ||
| The genetic basis of resistance to 5-fluorocytosine in Candida species and Cryptococcus neoformans | Q39685110 | ||
| Anti-Candida drugs--the biochemical basis for their activity | Q39685115 | ||
| Trichosporonosis in patients with neoplastic disease | Q39737308 | ||
| The genetics of medically important fungi | Q39761162 | ||
| Fluconazole resistance due to energy-dependent drug efflux in Candida glabrata | Q39780155 | ||
| The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans | Q39784510 | ||
| Reduced virulence of Candida albicans mutants affected in multidrug resistance | Q39823514 | ||
| Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits | Q39851052 | ||
| Uptake of itraconazole by alveolar macrophages | Q39865724 | ||
| Susceptibilities of serial Cryptococcus neoformans isolates from patients with recurrent cryptococcal meningitis to amphotericin B and fluconazole | Q39866233 | ||
| Effects of itraconazole on cytochrome P-450-dependent sterol 14 alpha-demethylation and reduction of 3-ketosteroids in Cryptococcus neoformans | Q39881922 | ||
| Characterization of an azole-resistant Candida glabrata isolate | Q40088759 | ||
| Fatal septicemia due to amphotericin B-resistant Candida lusitaniae. | Q40216477 | ||
| Development of amphotericin B-resistant Candida tropicalis in a patient with defective leukocyte function | Q40354286 | ||
| Sterol content and polyene antibiotic resistance in isolates of Candida krusei, Candida parakrusei, and Candida tropicalis | Q40647196 | ||
| Genetics and biochemistry of yeast multidrug resistance | Q40696620 | ||
| Is there a correlation between serum antifungal drug concentration and clinical outcome? | Q40698229 | ||
| Cryptococcal meningitis and AIDS. | Q40803349 | ||
| Fungal infections in solid-organ transplantation | Q40914902 | ||
| Lipid formulations of amphotericin B: recent progress and future directions | Q40941280 | ||
| In Vitro Studies of 5-Fluorocytosine Resistance in Candida albicans and Torulopsis glabrata | Q41028056 | ||
| Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature | Q41218000 | ||
| Fungal infections in lung and heart-lung transplant recipients. Report of 9 cases and review of the literature. | Q41269382 | ||
| Defective sterol C5-6 desaturation and azole resistance: a new hypothesis for the mode of action of azole antifungals | Q41273819 | ||
| Disseminated zygomycosis in a neutropenic patient: successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor | Q41440833 | ||
| A comparative review of colony-stimulating factors | Q41634907 | ||
| A Comparison of Amphotericin B Alone and Combined with Flucytosine in the Treatment of Cryptoccal Meningitis | Q41644134 | ||
| ATP-binding properties of P glycoprotein from multidrug-resistant KB cells. | Q42202109 | ||
| The lipid composition and permeability to azole of an azole- and polyene-resistant mutant of Candida albicans | Q42217506 | ||
| Correlation between in vitro and in vivo activity of antifungal agents against Candida species | Q42283580 | ||
| Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis | Q42287986 | ||
| Correlation between antifungal susceptibility testing of Candida isolates from patients with HIV infection and clinical results after treatment with fluconazole | Q42600087 | ||
| Zidovudine-resistant HIV strains in intravenous drug users and homosexual men in Amsterdam | Q43419846 | ||
| Increase inCandida kruseiInfection among Patients with Bone Marrow Transplantation and Neutropenia Treated Prophylactically with Fluconazole | Q43543160 | ||
| Oropharyngeal yeast flora and fluconazole resistance in HIV-infected patients receiving long-term continuous versus intermittent fluconazole therapy. | Q43702464 | ||
| Occurrence and characterization of acyclovir‐resistant herpes simplex virus isolates: Report on a two—year sensitivity screening survey | Q44354849 | ||
| Comparative morphological and biological studies on the itraconazole- and ketoconazole-resistant mutants of Cryptococcus neoformans | Q44532060 | ||
| Visceral fungal infections due to Petriellidium boydii (allescheria boydii). In vitro drug sensitivity studies | Q44553558 | ||
| Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis | Q44757473 | ||
| Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance | Q44986554 | ||
| Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients | Q45254690 | ||
| Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans | Q45763707 | ||
| Detection and significance of fluconazole resistance in oropharyngeal candidiasis in human immunodeficiency virus-infected patients | Q45767645 | ||
| A Mutation in Human Immunodeficiency Virus Reverse Transcriptase and Decline in CD4 Lymphocyte Numbers in Long-Term Zidovudine Recipients | Q45787062 | ||
| Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. | Q46047518 | ||
| Azole resistance in Candida albicans. | Q46470040 | ||
| René Dubos: a harbinger of microbial resistance to antibiotics | Q48853971 | ||
| Resistance to polyene antibiotics and correlated sterol changes in two isolates of Candida tropicalis from a patient with an amphotericin B-resistant funguria. | Q53743852 | ||
| Development of strains of Cryptococcus neoformans resistant to nystatin, amphotericin B, trichomycin and polymyxin B. | Q54029821 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 657-678 | |
| P577 | publication date | 1997-11-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches | |
| P478 | volume | 54 |
| Q34335250 | A clinical perspective for the management of invasive fungal infections: focus on IDSA guidelines. Infectious Diseases Society of America |
| Q44717183 | A new group of antifungal and antibacterial lipopeptides derived from non-membrane active peptides conjugated to palmitic acid |
| Q44557793 | A new method for studying the adhesion of Candida albicans to dentin in the presence or absence of smear layer |
| Q33874835 | Agents for treatment of invasive fungal infections |
| Q28343624 | Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action |
| Q43986534 | Antifungal and cancer cell growth inhibitory activities of 1-(3',4',5'-trimethoxyphenyl)-2-nitro-ethylene. |
| Q34594076 | Antifungal drug resistance of pathogenic fungi. |
| Q33973443 | Antifungal effects of lysozyme and lactoferrin against genetically similar, sequential Candida albicans isolates from a human immunodeficiency virus-infected southern Chinese cohort |
| Q43504868 | Antifungal rapamycin analogues with reduced immunosuppressive activity |
| Q33977460 | Antifungal resistance in yeast vaginitis |
| Q44589267 | Bioassay-guided isolation and identification of antifungal compounds from ginger |
| Q33340528 | Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome |
| Q33721804 | Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. |
| Q34133774 | Current and future approaches to antimycotic treatment in the era of resistant fungi and immunocompromised hosts |
| Q39088209 | DNA repair and mutations during quiescence in yeast |
| Q35710159 | Dendritic cell-based vaccination against opportunistic fungi |
| Q53659256 | Discovery, SAR, synthesis, pharmacokinetic and biochemical characterization of A-192411: a novel fungicidal lipopeptide-(I). |
| Q90435592 | Distribution of Candida albicans and non-albicans Candida species isolated in different clinical samples and their in vitro antifungal suscetibity profile in Ethiopia |
| Q35048626 | Effect of tetrandrine against Candida albicans biofilms |
| Q35566882 | Effects of magnolol and honokiol on adhesion, yeast-hyphal transition, and formation of biofilm by Candida albicans |
| Q77885966 | Evaluation of the use of xanthan as vehicle for cationic antifungal peptides |
| Q34775235 | Fungal infections associated with HIV infection |
| Q33961800 | Fungal resistance |
| Q33207493 | Genomic analysis of stationary-phase and exit in Saccharomyces cerevisiae: gene expression and identification of novel essential genes. |
| Q41561738 | Honokiol induces superoxide production by targeting mitochondrial respiratory chain complex I in Candida albicans |
| Q33971002 | Improved detection of amphotericin B-resistant isolates of Candida lusitaniae by Etest |
| Q42037361 | In Vitro Anti-Malassezia Activity of Castanea crenata Shell and Oil-Soluble Glycyrrhiza Extracts |
| Q28379512 | In vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts |
| Q42171868 | In vitro activity of eugenol against Candida albicans biofilms |
| Q34106775 | In vitro and in vivo antifungal activities of TAK-456, a novel oral triazole with a broad antifungal spectrum |
| Q33979652 | In vitro assessment of antifungal therapeutic potential of salivary histatin-5, two variants of histatin-5, and salivary mucin (MUC7) domain 1. |
| Q44301666 | In vivo characterization of A-192411: a novel fungicidal lipopeptide (II). |
| Q34348047 | Infectious morbidity in critically ill patients with cancer |
| Q33971165 | Influence of glucose supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida spp |
| Q44363819 | Inhibition of human pathogenic fungi by members of Zingiberaceae used by the Kenyah (Indonesian Borneo). |
| Q34131697 | Interplay between protective and inhibitory antibodies dictates the outcome of experimentally disseminated Candidiasis in recipients of a Candida albicans vaccine |
| Q36118209 | Isolation of quiescent and nonquiescent cells from yeast stationary-phase cultures |
| Q39475550 | Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy |
| Q33719828 | Metabolism-based drug interactions involving oral azole antifungals in humans |
| Q37365189 | Microbial drug discovery: 80 years of progress |
| Q28369468 | Mixture-based heterocyclic combinatorial positional scanning libraries: discovery of bicyclic guanidines having potent antifungal activities against Candida albicans and Cryptococcus neoformans |
| Q33888286 | Oral colonization by Candida albicans |
| Q82533255 | Penetratin analogues acting as antifungal agents |
| Q35229373 | Plant-derived antifungal agent poacic acid targets β-1,3-glucan |
| Q43690819 | Prevalence of vaginal colonization by drug-resistant Candida species in college-age women with previous exposure to over-the-counter azole antifungals |
| Q91639722 | Prevalence, Risk Factors, and Spectrum of Fungi in Patients with Onychomycosis in Addis Ababa, Ethiopia: A Prospective Study |
| Q33982572 | Prospective study of Candida species in patients at a comprehensive cancer center |
| Q33968704 | Rapid identification of Candida dubliniensis using a species-specific molecular beacon. |
| Q35666510 | SREBP-dependent triazole susceptibility in Aspergillus fumigatus is mediated through direct transcriptional regulation of erg11A (cyp51A). |
| Q40673323 | Synthesis and antifungal properties of N-[(1,1'-biphenyl)-4-ylmethyl]-1H-imidazol-1-amine derivatives |
| Q46424845 | Synthesis and biological activities of new hydrazide derivatives |
| Q42682476 | Synthesis, antifungal and antibacterial activity of novel 1,2,4-triazole derivatives |
| Q40306465 | The Structure-Activity Relationship of Pterostilbene Against Candida albicans Biofilms. |
| Q36376056 | Therapeutic activity of an engineered synthetic killer antiidiotypic antibody fragment against experimental mucosal and systemic candidiasis |
| Q73035266 | Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria |
| Q55340243 | Vulvovaginal candidiasis: species distribution of Candida and their antifungal susceptibility pattern. |
| Q42964578 | Xanthine oxidase/tyrosinase inhibiting, antioxidant, and antifungal oxindole alkaloids from Isatis costata |
Search more.